Trials / Terminated
TerminatedNCT01435772
Extension Study for Patients Who Have Participated in a BMN 701 Study
A Long-Term Study for Extended BMN 701 Treatment of Patients With Pompe Disease Who Have Participated in a BMN 701 Study
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- BioMarin Pharmaceutical · Industry
- Sex
- All
- Age
- 13 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2 open-label, multiple dose study of BMN 701 administered by IV infusion every 2 weeks (qow) to patients with late-onset Pompe disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | BMN 701 | GILT-tagged recombinant human GAA |
Timeline
- Start date
- 2011-08-15
- Primary completion
- 2016-09-09
- Completion
- 2016-09-09
- First posted
- 2011-09-19
- Last updated
- 2018-05-22
- Results posted
- 2018-05-22
Locations
12 sites across 6 countries: United States, Australia, France, Germany, New Zealand, United Kingdom
Source: ClinicalTrials.gov record NCT01435772. Inclusion in this directory is not an endorsement.